Skip to main content
OpenTrials
Recruiting

NCT Number: NCT04448639

Stunning in Takotsubo Versus Acute Myocardial Infarction

The Stunning in Takotsubo versus Acute Myocardial Infarction (STAMI) Study

Background: Acute myocardial stunning, herein defined as the reversible loss of myocardial function, occurs in both takotsubo syndrome (TS) and ST-elevation myocardial infarction (STEMI), and can be life-threatening in both conditions. However, despite typically having considerably more pronounced myocardial stunning, TS patients have better prognosis than patients with STEMI. Despite the different relationship between extent of myocardial stunning and prognosis in TS vs STEMI, no 'head-to-head' comparison of the myocardial stunning phenotypes in TS vs STEMI has been done.

Methods: The Stunning In Takotsubo and Acute Myocardial Infarction (STAMI) study is a single-center, prospective clinical study that will enroll 100 patients with STEMI and 25 patients with TS. Echocardiography, laboratory testing (including troponin and NTpro-BNP), and ECG will be done immediately after angiography and at days 1, 2, 3, 7, 14 and 30. The primary endpoint is the proportion of myocardial stunning that has resolved after 72 hours, as determined by echocardiography. Total myocardial stunning is defined as the extent of akinesia observed at day 0 that resolves by day 30.

Recruiting

Interested in participating?

Request Info

Key information

Sex eligibility

All sexes

Study type

Observational

Primary location

Department of Cardiology; Sahlgrenska University Hospital

Gothenburg, 413 45, Sweden

Location status: Recruiting

Location contact

Björn Redfors, MD, PhD

CONTACT

[email protected]

004631-342 7560;

Björn Redfors, MD, PhD

PRINCIPAL_INVESTIGATOR

Emanuele Bobbio, MD

SUB_INVESTIGATOR

Rickard Zeijlon, MD

SUB_INVESTIGATOR

Sandeep Jha, MD

CONTACT

[email protected]

0046738491912

Sandeep Jha, MD

SUB_INVESTIGATOR

Sigurdur Thorleifsson, MD

SUB_INVESTIGATOR

Thomas Mellberg, MD

SUB_INVESTIGATOR

About this study

Prospective assessment of the temporal electrocardiographic-, vectorcardiographic- and echocardiographic changes in STelevation myocardial infarction versus the takotsubo syndrome.

AIM To compare the temporal pattern of myocardial funtional recovery after ST-elevation myocardial infarction (STEMI) versus the takotsubo syndrome (TS).

BACKGROUND Modern therapies have reduced the incidence of acute ischemic heart failure (AIHF) -But AIHF is still common and once it develops prognosis remains dismal.Despite considerable therapeutic advancements over the last decades, acute myocardialinfarction (AMI) remains one of the most common causes of death . Among patients who are admitted with AMI, the 10% that develop AIHF account for approximately 50% of Deaths within 30 days . The prognosis for patients with AIHF has not improved over the last decade . AIHF occurs due to acute loss of cardiac function, some of which occurs in myocardium that is not irreparably damaged - so called stunned myocardium.

Myocardial stunning in AIHF - Temporary mechanical dysfunction without irreparable injury. Myocardial stunning was originally described in the setting of ischemia and was defined as temporary mechanical dysfunction that persists after resolution of ischemia, with the absence of irreversible histological damage . For the purpose of this application it is more broadly defined as temporary mechanical dysfunction, with the absence of irreversible histological damage - irrespective of the underlying cause. Myocardial stunning is believed to be a harmful phenomenon caused by cellular injury .

Study hypothesis: Myocardial stunning is a protective mechanism by which the cardiomyocytes preserve energy for vital processes in states of severe cellular stress - but that can "overshoot" and lead to potentially lethal cardiac decompensation. In the normal heart, the contractile apparatus consumes the majority of myocardial energy and oxygen . Non-contractile myocardial functions, including cellular and electrical homeostasis, require less than 20% as much oxygen. When oxygen supply to the heart is interrupted myocardial stunning ensues within seconds, whereas it takes at least 10 minutes for the cardiomyocyte's energy metabolites to decrease to 50% of their initial level .Hence, by shutting down the contractile apparatus before it consumes the cells' energy stores myocardial stunning effectively preserves energy for processes that are necessary for cell survival . Irrespective of its beneficial effects on cardiomyocyte metabolism, myocardial stunning may lead to sufficiently pronounced cardiac dysfunction to cause life-threatening AIHF.

Study purpose:

To better understand the difference between myocardial stunning in STEMI and the more benign form of stunning in TS. The sudden occurrence of temporary myocardial mechanical dysfunction with the absence of irreversible myocardial damage is not limited to AMI. It can occur postoperatively after cardiac arrest; in the settings of acute myocarditis and tachycardia-induced cardiomyopathy; and as a consequence of severe emotional or somatic stress in the takotsubo syndrome .Intriguingly, takotsubo is characterized by a compensated hemodynamic profile despite extensive myocardial dysfunction, effective recovery of myocardial function within days orweeks, and a relatively good prognosis .Takotsubo therefore appears to be a more efficient form of stunning than AIHF. Better understanding of the mechanisms behind the stunning phenomenon could allow for manipulation of the stunning phenotype in AIHF, or for pharmacological reversal of myocardial stunning once coronary reperfusion and adequate myocardial energy delivery has been ensured.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • STEMI or TS with planned coronary angiography within 12 hours from the onset of symptoms
  • Written consent

Exclusion criteria

  • Cardiogenic shock, defined as Killip class IV
  • Expected inability to comply with the protocol

Treatment and study plan

Echocardigraphy (ECHO)

Diagnostic Test

Standar 12 lead electrocardiogram

Other names: Standard electrocardigraphy (ECG )

Bloodtest

Diagnostic Test

cardiac biomarkers

Other names: Troponin and NT-proBNP

Primary outcomes

  1. Proportion of stunning that has resolved at 3 days versus 14 days

    Time frame: 30 days

    StunningResolution at 3 days is defined as StunningRes3D = (%Akinesia Baseline - %Akinesia 3day) / (%Akinesia Baseline -

    %Akinesia 30days); where %Akinesia is calculated as the endocardial length of the akinetic left ventricular myocardium divided by the total endocardial length of the left ventricular myoocardium - as assessed in the apical 2-chamber and 4-chamber views at end-diastole.

    The recovery of stunning at 3 days is compared to the recovery of stunning at 30 days. Thus a 14 day timeframe is required.

Secondary outcomes

  1. Change in wall motion score index

    Time frame: 30 days

    Myocardial wall motion score index

  2. Change in left ventricular ejection fraction

    Time frame: 30 days

    left ventricular ejection fraction as measured by speckle tracking echocardiography.

  3. Change in global longitudinal strain

    Time frame: 30 days

    Global longitudinal strain as measured by speckle tracking echocardiography.

  4. Change in radial strain in the unaffected contralateral myocardial wall

    Time frame: 30 days

    Radial longitudinal strain as measured by speckle tracking echocardiography.

  5. Change in serum troponin-I:troponin:T ratio

    Time frame: 30 days

    The ratio between serum troponin-1 and serum troponin-T

  6. Change in serum NT proBNP

    Time frame: 30 days

    Serum NT proBNP

Sponsors and collaborators

Lead sponsor

Vastra Gotaland Region

Other Gov

Registry information

Official study title

STAMI- Stunning in Takotsubo Versus Acute Myocardial Infarction

Acronym: STAMI

Important dates

Study start
2019
Primary completion
2024
Study completion
2030
First posted
Jun 26, 2020
Registry last updated
Dec 12, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.